<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmacoepidemiol Drug Saf</journal-id><journal-id journal-id-type="iso-abbrev">Pharmacoepidemiol Drug Saf</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Pharmacoepidemiology and drug safety</journal-title></journal-title-group><issn pub-type="ppub">1053-8569</issn><issn pub-type="epub">1099-1557</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11309576</article-id><article-id pub-id-type="pmcid-ver">PMC11309576.1</article-id><article-id pub-id-type="pmcaid">11309576</article-id><article-id pub-id-type="pmcaiid">11309576</article-id><article-id pub-id-type="manuscript-id">NIHMS1998446</article-id><article-id pub-id-type="pmid">39099262</article-id><article-id pub-id-type="doi">10.1002/pds.5852</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1998446</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1998446</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Risk of Suicidal Ideation and Behavior Following Early-Onset Idiopathic Restless Legs Syndrome Treatment</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5334-2712</contrib-id><name name-style="western"><surname>Costales</surname><given-names initials="B">Brianna</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0411-2160</contrib-id><name name-style="western"><surname>Vouri</surname><given-names initials="SM">Scott M.</given-names></name><degrees>PhD, PharmD, BCGP</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2973-1021</contrib-id><name name-style="western"><surname>Brown</surname><given-names initials="JD">Joshua D.</given-names></name><degrees>PhD, PharmD</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9133-9445</contrib-id><name name-style="western"><surname>Setlow</surname><given-names initials="B">Barry</given-names></name><degrees>PhD</degrees><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0020-8720</contrib-id><name name-style="western"><surname>Goodin</surname><given-names initials="AJ">Amie J.</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib></contrib-group><aff id="A1"><label>1.</label>Department of Pharmaceutical Outcomes &amp; Policy, University of Florida, College of Pharmacy, Gainesville, FL, USA</aff><aff id="A2"><label>2.</label>Center for Drug Evaluation &amp; Safety, Department of Pharmaceutical Outcomes &amp; Policy, University of Florida, College of Pharmacy, Gainesville, FL, USA</aff><aff id="A3"><label>3.</label>Department of Psychiatry, University of Florida, College of Medicine, Gainesville, FL, USA</aff><author-notes><fn fn-type="other" id="FN1"><p id="P1">About the Authors</p><p id="P2">Brianna Costales, PhD</p><p id="P3">Address: 1225 Center Drive, Gainesville, FL, 32610-0496, USA</p><p id="P4">Scott M. Vouri, PhD, PharmD, BCGP</p><p id="P5">Address: 1225 Center Drive, Gainesville, Florida, 32610-0496, USA</p><p id="P6">Joshua D. Brown, PhD, PharmD</p><p id="P7">Address: 1225 Center Drive, Gainesville, Florida, 32610-0496, USA</p><p id="P8">Barry Setlow, PhD</p><p id="P9">Address: Department of Psychiatry, University of Florida, PO Box 100256, Gainesville, Florida, 32610-0256, USA</p><p id="P10">Amie J. Goodin, PhD</p><p id="P11">Address: 1225 Center Drive, Gainesville, Florida, 32610-0496, USA</p></fn><corresp id="CR1"><label>*</label>Corresponding author at: 1225 Center Drive, Gainesville, Florida, 32610-0496, USA, <email>amie.goodin@ufl.edu</email></corresp><fn fn-type="COI-statement" id="FN2"><p id="P49">Conflict of Interest</p><p id="P50">S.M. Vouri is currently employed by Pfizer, Inc. This work occurred while working for the University of Florida and outside of his capacity at Pfizer.</p><p id="P51">J.D. Brown is currently employed by Pfizer, Inc. This work occurred while working for the University of Florida and outside of his capacity at Pfizer.</p><p id="P52">Authors B. Costales, B. Setlow, and A.J. Goodin report no conflict of interest.</p></fn></author-notes><pub-date pub-type="ppub"><month>8</month><year>2024</year></pub-date><volume>33</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">468396</issue-id><fpage>e5852</fpage><lpage>e5852</lpage><pub-history><event event-type="nihms-submitted"><date><day>01</day><month>06</month><year>2024</year></date></event><event event-type="pmc-release"><date><day>01</day><month>08</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-08-28 17:25:27.790"><day>28</day><month>08</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1998446.pdf"/><abstract id="ABS1"><sec id="S1"><title>Purpose:</title><p id="P12">To estimate incidence rates of suicidal ideation and behavior following treatment initiation with gabapentinoids or dopamine agonists (DAs) in patients with newly diagnosed early-onset idiopathic restless legs syndrome (RLS); and examine suicidal behavior risk, comparing between those receiving gabapentinoids and DAs.</p></sec><sec id="S2"><title>Methods:</title><p id="P13">A new user retrospective cohort study using MarketScan claims data from 2012&#8211;2019 was conducted. Exposures were monotherapy gabapentinoids or DAs initiated within 60 days of new RLS diagnosis. Three varying outcome measures of suicidality were examined and incidence rates were calculated for each. A log-binomial regression model estimated relative risk (RR) of the outcomes with gabapentinoids. Propensity score weighting adjusted for baseline covariates, including age, substance use disorders, hyperlipidemia, antipsychotic use, hypnotic/sedative use, and mood stabilizer use which were most imbalanced before weighting.</p></sec><sec id="S3"><title>Results:</title><p id="P14">The cohort included 6,672 patients, with 4,986 (74.7%) initiating a DA and 1,686 (25.3%) initiating a gabapentinoid. Incidence rates for all outcome measures were higher in the gabapentinoid group (suicidality: 21.6 vs. 10.7 per 1,000 person-years; suicidality with self-harm: 23.0 vs. 11.1 per 1,000 person-years; overdose- and suicide-related events: 30.0 vs. 15.5 person-years). Associated risk of suicidality (adjusted RR, 1.27 [95% CI, 0.86&#8211;1.88]); suicidality with self-harm (adjusted RR, 1.30 [95% CI, 0.89&#8211;1.90]); or overdose- and suicide-related events (adjusted RR, 1.30 [95% CI, 0.93&#8211;1.80]) was not significant with gabapentinoids.</p></sec><sec id="S4"><title>Conclusions:</title><p id="P15">Incidence rates for suicidal ideation and behavior were higher among the gabapentinoid group, although increased risk was not detected after adjustment. A possible signal cannot be ruled out given limitations of the data and rarity of the outcome.</p></sec></abstract><abstract id="ABS2" abstract-type="summary"><title>Plain Language Summary</title><p id="P16">We looked at how often patients with a certain type of neurological and sleep disorder, known as restless legs syndrome (RLS), had thoughts about self-harm or hurt themselves after starting a medication for RLS. We focused on two types of medicines commonly prescribed for RLS: gabapentinoids and dopamine agonists (DAs). Using information from health insurance, we looked at records from over 6,000 patients with RLS. If they started a gabapentinoid or DA after diagnosis, we analyzed how often they experienced suicide-related behaviors and we measured whether their risk of these thoughts or behaviors were more likely to occur with either of the types of medicines. We made sure the people taking each type of medicine were similar enough to be comparable before we measured their risks. We found that most patients were treated with a DA and about one-fourth were treated with a gabapentinoid. Although people taking the gabapentinoids experienced self-harm more often than people taking the DAs, this risk was not statistically significant. This means that we cannot definitively say self-harm thoughts and behavior was because of the medication. Our research highlights the need to better understand whether gabapentinoids could cause mental health risks when used to treat RLS.</p></abstract><kwd-group><kwd>restless legs syndrome</kwd><kwd>Willis-Ekbom disease</kwd><kwd>idiopathic</kwd><kwd>dopamine agonists</kwd><kwd>gabapentinoids</kwd><kwd>suicidal ideation</kwd><kwd>self-injurious behavior</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-exception-type</meta-name><meta-value>EMBARGO</meta-value></custom-meta><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>4</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>no</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>